|
|
???tair.name??? >
???browser.page.title.author???
|
"su w c"???jsp.browse.items-by-author.description???
Showing items 1-25 of 419 (17 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
|
Hartmaier, R.J.;Markovets, A.A.;Ahn, M.J.;Sequist, L.V.;Han, J.-Y.;Cho, B.C.;Yu, H.A.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.-S.;Su, W.-C.;Kowalski, D.M.;Orlov, S.;Ren, S.;Frewer, P.;Ou, X.;Cross, D.A.E.;Kurian, N.;Cantarini, M.;J�nne, P.A. |
| 國立成功大學 |
2023 |
Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population
|
Shi, J.;Shiraishi, K.;Choi, J.;Matsuo, K.;Chen, T.-Y.;Dai, J.;Hung, R.J.;Chen, K.;Shu, X.-O.;Kim, Y.T.;Landi, M.T.;Lin, D.;Zheng, W.;Yin, Z.;Zhou, B.;Song, B.;Wang, J.;Seow, W.J.;Song, L.;Chang, I.-S.;Hu, W.;Chien, L.-H.;Cai, Q.;Hong, Y.-C.;Kim, H.N.;Wu, Y.-L.;Wong, M.P.;Richardson, B.D.;Funderburk, K.M.;Li, S.;Zhang, T.;Breeze, C.;Wang, Z.;Blechter, Blechter B.;Bassig, Bassig B.A.;Kim, J.H.;Albanes, D.;Wong, J.Y.Y.;Shin, M.-H.;Chung, L.P.;Yang, Yang Y.;An, S.-J.;Zheng, H.;Yatabe, Yatabe Y.;Zhang, X.-C.;Kim, Y.-C.;Caporaso, N.E.;Chang, J.;Ho, J.C.M.;Kubo, M.;Daigo, Y.;Song, M.;Momozawa, Y.;Kamatani, Y.;Kobayashi, M.;Okubo, K.;Honda, T.;Hosgood, D.H.;Kunitoh, H.;Patel, H.;Watanabe, S.-I.;Miyagi, Y.;Nakayama, H.;Matsumoto, S.;Horinouchi, Horinouchi H.;Tsuboi, M.;Hamamoto, R.;Goto, K.;Ohe, Y.;Takahashi, A.;Goto, A.;Minamiya, Y.;Hara, M.;Nishida, Y.;Takeuchi, K.;Wakai, K.;Matsuda, K.;Murakami, Y.;Shimizu, K.;Suzuki, H.;Saito, M.;Ohtaki, Y.;Tanaka, K.;Wu, T.;Wei, F.;Dai, H.;Machiela, Machiela M.J.;Su, J.;Kim, Y.H.;Oh, I.-J.;Lee, V.H.F.;Chang, G.-C.;Tsai, Y.-H.;Chen, K.-Y.;Huang, M.-S.;Su, W.-C.;Chen, Y.-M.;Seow, A.;Park, J.Y.;Kweon, S.-S.;Chen, K.-C.;Gao, Y.-T.;Qian, B.;Wu, C.;Lu, D.;Liu, J.;Schwartz, A.G.;Houlston, R.;Spitz, M.R.;Gorlov, I.P.;Wu, X.;Yang, P.;Lam, S.;Tardon, A.;Chen, Chen C.;Bojesen, S.E.;Johansson, M.;Risch, A.;Bickeb�ller, H.;Ji, B.-T.;Wichmann, H.-E.;Christiani, D.C.;Rennert, G.;Arnold, S.;Brennan, P.;McKay, J.;Field, J.K.;Shete, Shete S.S.;Le, Marchand L.;Liu, G.;Andrew, Andrew A.;Kiemeney, L.A.;Zienolddiny-Narui, S.;Grankvist, K.;Johansson, M.;Cox, A.;Taylor, F.;Yuan, J.-M.;Lazarus, P.;Schabath, M.B.;Aldrich, M.C.;Jeon, H.-S.;Jiang, S.S.;Sung, J.S.;Chen, Chen C.-H.;Hsiao, C.-F.;Jung, Y.J.;Guo, H.;Hu, Z.;Burdett, L.;Yeager, M.;Hutchinson, A.;Hicks, B.;Liu, J.;Zhu, B.;Berndt, S.I.;Wu, Wu W.;Wang, J.;Li, Y.;Choi, J.E.;Park, K.H.;Sung, Sung S.W.;Liu, Liu L.;Kang, C.H.;Wang, Wang W.-C.;Xu, J.;Guan, P.;Tan, W.;Yu, C.-J.;Yang, G.;Sihoe, A.D.L.;Chen, Y.;Choi, Y.Y.;Kim, J.S.;Yoon, H.-I.;Park, I.K.;Xu, P.;He, Q.;Wang, C.-L.;Hung, Hung H.-H.;Vermeulen, R.C.H.;Cheng, I.;Wu, J.;Lim, W.-Y.;Tsai, F.-Y.;Chan, J.K.C.;Li, J.;Chen, H.;Lin, H.-C.;Jin, L.;Liu, J.;Sawada, N.;Yamaji, T.;Wyatt, K.;Li, S.A.;Ma, H.;Zhu, M.;Wang, Z.;Cheng, S.;Li, X.;Ren, Y.;Chao, A.;Iwasaki, M.;Zhu, J.;Jiang, G.;Fei, K.;Wu, G.;Chen, Chen C.-Y.;Chen, Chen C.-J.;Yang, P.-C.;Yu, J.;Stevens, V.L.;Fraumeni, J.F.;Jr;Chatterjee, N.;Gorlova, O.Y.;Hsiung, C.A.;Amos, C.I.;Shen, H.;Chanock, S.J.;Rothman, N.;Kohno, T.;Lan, Q. |
| 國立成功大學 |
2023 |
Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
|
Yang, S.-C.;Ou, H.-T.;Su, W.-C.;Wang, S.-Y. |
| 國立成功大學 |
2023 |
Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer
|
Wang, C.-L.;Hsu, K.-H.;Chang, Y.-H.;Ho, C.-C.;Chiang, Chiang C.-J.;Chen, K.-C.;Cheung, Y.-C.;Huang, P.-C.;Chen, Y.-R.;Chen, Chen C.-Y.;Hsu, C.-P.;Hsia, J.-Y.;Chen, H.-Y.;Yang, S.-Y.;Li, Y.-J.;Yang, T.-Y.;Tseng, J.-S.;Chuang, Chuang C.-Y.;Hsiung, C.A.;Chen, Y.-M.;Huang, M.-S.;Yu, C.-J.;Chen, K.-Y.;Su, W.-C.;Chen, J.J.W.;Yu, S.-L.;Chen, Chen C.-J.;Yang, P.-C.;Tsai, Y.-H.;Chang, G.-C. |
| 國立成功大學 |
2023 |
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
|
John, T.;Groh�, C.;Goldman, J.W.;Shepherd, F.A.;de, Marinis F.;Kato, T.;Wang, Q.;Su, W.-C.;Choi, J.H.;Sriuranpong, V.;Melotti, B.;Fidler, M.J.;Chen, J.;Albayaty, M.;Stachowiak, M.;Taggart, S.;Wu, Y.-L.;Tsuboi, M.;Herbst, R.S.;Majem, Majem M. |
| 國立成功大學 |
2023 |
Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan
|
Blechter, Blechter B.;Chien, L.-H.;Chen, T.-Y.;Chang, I.-S.;Choudhury, P.P.;Hsiao, C.-F.;Shu, X.-O.;Wong, J.Y.Y.;Chen, K.-Y.;Chang, G.-C.;Tsai, Y.-H.;Su, W.-C.;Huang, M.-S.;Chen, Y.-M.;Chen, Chen C.-Y.;Hung, Hung H.-H.;Hu, J.-W.;Shi, J.;Zheng, W.;Rositch, A.F.;Chen, Chen C.-J.;Chatterjee, N.;Yang, P.-C.;Rothman, N.;Hsiung, C.A.;Lan, Q. |
| 國立成功大學 |
2023 |
Occupational evaluation of community-based psychiatric rehabilitation outcomes in individuals with severe mental illnesses: A ten-year retrospective study
|
Liu, Y.-C.;Yang, Yang Y.K.;Lee, Y.-C.;Lin, S.-H.;Hsu, W.-Y.;Su, W.-C.;Chen, K.C.;Lin, K.-C. |
| 國立成功大學 |
2023 |
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-na�ve, cisplatin-ineligible urothelial cancer
|
Galffy, Galffy G.;Lugowska, I.;Poddubskaya, E.V.;Cho, B.C.;Ahn, M.-J.;Han, J.-Y.;Su, W.-C.;Hauke, R.J.;Dyar, S.H.;Lee, D.H.;Serwatowski, P.;Estelles, D.L.;Holden, V.R.;Kim, Y.J.;Vladimirov, Vladimirov V.;Horvath, Z.;Ghose, A.;Goldman, A.;di, Pietro A.;Wang, J.;Murphy, D.A.;Alhadab, Alhadab A.;Laskov, M. |
| 國立成功大學 |
2023 |
Thiamet G as a Potential Treatment for Polycystic Kidney Disease
|
Su, W.-C.;Hung, C.-F.;Wang, Y.-C.;Peng, H.;Huang, W.-H.;Lo, Y.-L.;Lo, Y.-H.;Chen, Y.-C.;Su, H.-H.;Chen, Y.-L. |
| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 國立成功大學 |
2023 |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
|
Chiu, Chiu C.-H.;Lin, M.-C.;Wei, Y.-F.;Chang, G.-C.;Su, W.-C.;Hsia, T.-C.;Su, J.;Wang, A.K.-F.;Jen, M.-H.;Puri, T.;Shih, J.-Y. |
| 國立成功大學 |
2023 |
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
|
Camidge, D.R.;Barlesi, F.;Goldman, J.W.;Morgensztern, D.;Heist, R.;Vokes, E.;Spira, A.;Angevin, E.;Su, W.-C.;Hong, D.S.;Strickler, J.H.;Motwani, Motwani M.;Dunbar, M.;Parikh, A.;Noon, E.;Blot, V.;Wu, J.;Kelly, Kelly K. |
| 國立成功大學 |
2023 |
PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target
|
Singh, Singh S.;Yeat, N.Y.;Wang, Y.-T.;Lin, S.-Y.;Kuo, I.-Y.;Wu, K.-P.;Wang, Wang W.-J.;Wang, Wang W.-C.;Su, W.-C.;Wang, Y.-C.;Chen, R.-H. |
| 國立成功大學 |
2023 |
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
|
Tsuboi, M.;Herbst, R.S.;John, T.;Kato, T.;Majem, Majem M.;Groh�, C.;Wang, J.;Goldman, J.W.;Lu, S.;Su, W.-C.;De, Marinis F.;Shepherd, F.A.;Lee, K.H.;Le, N.T.;Dechaphunkul, A.;Kowalski, D.;Poole, L.;Bolanos, A.;Rukazenkov, Y.;Wu, Y.-L. |
| 國立成功大學 |
2023 |
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
|
Yang, J.C.-H.;Su, W.-C.;Chiu, Chiu C.-H.;Shiah, H.-S.;Lee, K.-Y.;Hsia, T.-C.;Uno, M.;Crawford, N.;Terakawa, H.;Chen, W.-C.;Takayama, G.;Hsu, C.;Hong, Y.;Saintilien, C.;McGill, J.;Chang, G.-C. |
| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; Chia-Chi Lin; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah H.-S.; Chiang N.-J.; Chia-Chi Lin; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. |
| 臺大學術典藏 |
2022-09-15T01:08:46Z |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Chia-Chi Lin; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; Shen Y.-C.; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
CHIH-HSIN YANG; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; CHIH-HSIN YANG; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2022-08-10T02:37:37Z |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-08-10T02:37:37Z |
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
|
J?nne P.A.; Baik C.; Su W.-C.; Johnson M.L.; Hayashi H.; Nishio M.; Kim D.-W.; Koczywas M.; Gold K.A.; Steuer C.E.; Murakami H.; CHIH-HSIN YANG; Kim S.-W.; Vigliotti M.; Shi R.; Qi Z.; Qiu Y.; Zhao L.; Sternberg D.; Yu C.; Yu H.A. |
Showing items 1-25 of 419 (17 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
|
